Clinicopathological features of bladder tumours in a single institution in Malaysia

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 1, 2010, Pages 149-152

  Kong, Christopher Ho Chee ^a   Singam, Praveen ^a   Hong, Goh Eng ^a   Cheok, Lee Boon ^a   Azrif, Muhammad ^a   Tamil, Azmi Mohd ^a   Zainuddin, Zulkifli Md ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

Bladder; Demography; Survival; Tumour; Urinary bladder neoplasm

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; CLINICAL TRIAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALAYSIA; MALE; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALAYSIA; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 77955823472     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Carrion R, Seigne J (2002). Surgical management of bladder carcinoma. Cancer Control, 9, 284-92.
2. Epstein JI, Amin MB, Reuter VR, Mostofi FK (1998). The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol, 22, 1435-48.
3. Gupta P, Jain M, Kapoor R, et al (2009). Impact of age and gender on the clinicopathological characteristics of bladder cancer. Indian J Urol, 25, 207-10.
4. Hartge P, Harvey EB, Linehan WM, et al (1990). Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst, 82, 1636-40
5. Horn EP, Tucker Ma, Lambert G, et al (1995). A study of gender-based cytochrome P450 1A2 variability: A possible mechanism for the male excess of bladder cancer. Cancer Epidemiol Biomarkers Prev, 4, 529-33
6. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009). Cancer statistics. CA Cancer J Clin, 59, 225-249
7. Johansson SL, Cohen SM (1997). Epidemiology and etiology of bladder cancer. Semin Surg Oncol, 13, 291-8
8. Logothetis CJ, Dexeus FH, Chong C, et al (1989). Cisplatin, cyclophosphamide and doxorubicin chemotherapy for unresectable urothelial tumors: the M.D. Anderson experience. J Urol, 141, 33-7.
9. Matalka I, Bani-Hani K, Shotar A, Bani Hani O, Bani-Hani I (2008). Transitional cell carcinoma of the urinary bladder: a clinicopathological study. Singapore Med J, 49, 790-4.
10. Messing EM, Young TB, Hunt VB, et al (1995). Comparison of bladder cancer outcome in men undergoing hematuria home screening versus those with standard clinical presentations. Urology, 45, 387-96
11. Rabbani F, Cordon-Cardo C (2000). Mutation of cell cycle regulators and their impact on superficial bladder cancer. Urol Clin North Am, 27, 83-102
12. Skinner DG, Daniels JR, Russell CA, et al (1991). The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol, 145, 459-64.
13. Sobin LH, Wittekind CH (2002). International Union Against Cancer (UICC): TNM Classification of malignant tumours, 6th ed. Wiley-Liss, New York, pp 184-7.
14. Sternberg CN, Yagoda A, Scher HI, et al (1989). Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer, 64, 2448-58.
15. Türkölmez K, Tokgöz H, Regorlu B, Köse K, Bedük Y (2007). Muscle-invasive bladder cancer: predictive factors and prognostic difference between primary and progressive tumors. Urology, 70, 477-81.
16. Vallancien G, Abou El Fettouh H, Cathelineau X, et al (2002). Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol, 168, 2413-7.
17. Zainal AO, Zainuddin MA, Nor Saleha IT (2006). Malaysian Cancer Statistics-Data and Figure Peninsular Malaysia 2006. National Cancer Registry, Ministry of Health Malaysia.